Ferric derisomaltose
Ferric derisomaltose, sold under the brand name Monoferric, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD).[1] It was approved for use in the United States in January 2020.[1][2][3] It is given intravenously.[1]
| Clinical data | |
|---|---|
| Trade names | Monoferric |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous (IV) |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H34FeO16+3 |
| Molar mass | 562.299 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- "Monoferric- ferric derisomaltose solution". DailyMed. 24 January 2020. Retrieved 16 February 2020.
- "Monoferric approval letter" (PDF). U.S. Food and Drug Administration (FDA). 16 January 2020. Retrieved 16 February 2020.
This article incorporates text from this source, which is in the public domain. - "Drug Approval Package: Monoferric Injection". U.S. Food and Drug Administration (FDA). 7 May 2020. Retrieved 13 August 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.